Ocular Therapeutix up 6% premarket on Dextenza reimbursement code
Ocular Therapeutix (NASDAQ:OCUL) is up 6% premarket on average volume in reaction to the establishment of a specific Medicare reimbursement codefor DEXTENZA (dexamethasone ophthalmic insert). The code will take effect on October 1.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.